Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener klinische Wochenschrift
Erschienen in:

11.09.2024 | original article

Obesity might not alter tofacitinib drug survival in rheumatoid arthritis patients

verfasst von: Esra Kayacan Erdoğan, MD, Berkan Armağan, MD, Rezan Koçak Ulucaköy, MD, Kevser Orhan, MD, Serdar Can Güven, MD, Bahar Özdemir Ulusoy, MD, Hatice Ecem Konak, MD, Özlem Karakaş, MD, Pınar Akyüz Dağlı, MD, Ebru Atalar, MD, İsmail Doğan, MD, Yüksel Maraş, MD, Ahmet Omma, MD, Orhan Küçükşahin, MD, Şükran Erten, MD, Hakan Babaoğlu, MD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 1-2/2025

Einloggen, um Zugang zu erhalten

Summary

Introduction

Obese rheumatoid arthritis (RA) patients often show reduced responses to traditional treatments, including TNF inhibitors (TNFi). Considering the different mechanisms of action it is important to evaluate the efficacy of tofacitinib in obese patients. This study aims to explore the impact of obesity on the drug survival of tofacitinib in RA patients.

Material and methods

This retrospective cohort study included RA patients treated with tofacitinib. Patients were categorized into obese (BMI ≥ 30 kg/m2) and non-obese (BMI < 30 kg/m2) groups. The primary outcome was drug survival, assessed using Kaplan-Meier and logistic regression analyses.

Results

The study comprised 80 RA patients, with 31 (39%) classified as obese. At the 12-month mark, the drug survival rate for tofacitinib was higher in the obese group (81%) compared to the non-obese group (59%). Contrary to univariable analysis, multivariate analysis did not identify obesity as a significant predictor of drug survival. Other variables including sex, hypertension, diabetes mellitus, and anti–cyclic citrullinated peptide (anti-CCP) positivity also showed no significant association with tofacitinib drug survival.

Conclusion

The findings indicate that obesity does not alter the drug survival rate for tofacitinib among RA patients. Univariate analysis reported a potentially higher drug survival rate in obese patients; however, the lack of statistical significance in multivariate analysis and the study’s retrospective nature necessitate further research to validate these observations and guide personalized therapeutic strategies for this population.
Vorheriger Artikel Predictors of static and dynamic balance control in kidney transplant recipients
Nächster Artikel Treatment of fecal incontinence—is there a light in the end of the tunnel?
Literatur
1.
2.
Moroni L, Farina N, Dagna L. Obesity and its role in the management of rheumatoid and psoriatic arthritis. Clin Rheumatol. 2020;39:1039–47.CrossRefPubMed
3.
Giles JT, Ogdie A, Gomez-Reino JJ, Helliwell PS, Germino R, Stockert L, et al. Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis. RMD Open. 2021;7(1):e1486.CrossRefPubMedPubMedCentral
4.
Popko K, Gorska E, Stelmaszczyk-Emmel A, Plywaczewski R, Stoklosa A, Gorecka D, et al. Proinflammatory cytokines Il‑6 and TNF‑α and the development of inflammation in obese subjects. Eur J Med Res. 2010;15:1–3.CrossRef
5.
Feng J, Chen Q, Yu F, Wang Z, Chen S, Jin Z, et al. Body mass index and risk of rheumatoid arthritis: a meta-analysis of observational studies. Medicine. 2016;95:8.CrossRef
6.
Ellerby N, Mattey DL, Packham J, Dawes P, Hider SL. Obesity and comorbidity are independently associated with a failure to achieve remission in patients with established rheumatoid arthritis. Ann Rheum Dis. 2014;73(11):e74‑e.CrossRef
7.
Kaeley GS, MacCarter DK, Pangan AL, Wang X, Kalabic J, Ranganath VK. Clinical responses and synovial vascularity in obese rheumatoid arthritis patients treated with adalimumab and methotrexate. J Rheumatol. 2018;45(12):1628–35.CrossRefPubMed
8.
Cohen SB, Pope J, Haraoui B, Mysler E, Diehl A, Lukic T, et al. Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift). RMD Open. 2021;7(2):e1673.CrossRefPubMedPubMedCentral
9.
Dikranian AH, Gonzalez-Gay MA, Wellborne F, Álvaro-Gracia JM, Takiya L, Stockert L, et al. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies. RMD Open. 2022;8(1):e2103.CrossRefPubMedPubMedCentral
10.
Project TJ. Jamovi. Version 2.3 ed2022.
11.
Rosenberg V, Chodick G, Xue Z, Faccin F, Amital H. Real-world data of adherence and drug survival of biologics in treatment-naïve and treatment-experienced adult patients with rheumatoid arthritis. Adv Ther. 2023; 1–19.
12.
Movahedi M, Choquette D, Coupal L, Cesta A, Li X, Keystone EC, et al. Discontinuation of tofacitinib and TNF inhibitors in patients with rheumatoid arthritis: analysis of pooled data from two registries in Canada. BMJ Open. 2023;13(3):e63198.CrossRefPubMedPubMedCentral
13.
Pope J, Bessette L, Jones N, Fallon L, Woolcott J, Gruben D, et al. Experience with tofacitinib in Canada: patient characteristics and treatment patterns in rheumatoid arthritis over 3 years. Rheumatology. 2020;59(3):568–74.PubMed
14.
Bilgin E, Ceylan F, Duran E, Farisoğullari B, Bölek EÇ, Yardimci GK, et al. Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience. Turk J Med Sci. 2021;51(1):297–308.CrossRefPubMedPubMedCentral
15.
Karatas A, Gur B, Oz B, Piskin Sagir R, Hohluoglu A, Gozel N, et al. The 6‑month drug survival rate in patients with rheumatoid arthritis treated with tofacitinib. 2021.
16.
Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K, et al. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Sci Rep. 2022;12(1):134.CrossRefPubMedPubMedCentral
17.
Finckh A, Tellenbach C, Herzog L, Scherer A, Moeller B, Ciurea A, et al. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland. RMD Open. 2020;6(1):e1174.CrossRefPubMedPubMedCentral
18.
de Resende Guimarães MFB, Rodrigues CEM, Gomes KWP, et al. High prevalence of obesity in rheumatoid arthritis patients: association with disease activity, hypertension, dyslipidemia and diabetes, a multi-center study. Adv Rheumatol. 2019;59:44.CrossRefPubMed
19.
Elalouf O, Lidar M, Reitblat T, Zisman D, Balbir-Gurman A, Hakakian O, et al. High body mass index is associated with shorter retention of tumor necrosis factor-alpha blocker treatment in rheumatoid arthritis. Biologics. 2021; 279–87.
20.
Bergstra SA, Allaart CF, Vega-Morales D, De Buck M, Murphy E, Escoto KS, et al. Body mass index and treatment survival in patients with RA starting treatment with TNFα-inhibitors: long-term follow-up in the real-life METEOR registry. RMD Open. 2020;6(2):e1203.CrossRefPubMedPubMedCentral
21.
Singh S, Facciorusso A, Singh AG, Casteele NV, Zarrinpar A, Prokop LJ, et al. Obesity and response to anti-tumor necrosis factor‑α agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS ONE. 2018;13(5):e195123.CrossRefPubMedPubMedCentral
22.
Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6(10):772–83.CrossRefPubMed
23.
Shan J, Zhang J. Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: a systematic review and meta-analysis. Joint Bone Spine. 2019;86(2):173–83.CrossRefPubMed
Metadaten
Titel
Obesity might not alter tofacitinib drug survival in rheumatoid arthritis patients
verfasst von
Esra Kayacan Erdoğan, MD
Berkan Armağan, MD
Rezan Koçak Ulucaköy, MD
Kevser Orhan, MD
Serdar Can Güven, MD
Bahar Özdemir Ulusoy, MD
Hatice Ecem Konak, MD
Özlem Karakaş, MD
Pınar Akyüz Dağlı, MD
Ebru Atalar, MD
İsmail Doğan, MD
Yüksel Maraş, MD
Ahmet Omma, MD
Orhan Küçükşahin, MD
Şükran Erten, MD
Hakan Babaoğlu, MD
Publikationsdatum
11.09.2024
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 1-2/2025
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-024-02424-3

Weitere Artikel der Ausgabe 1-2/2025

Masqueraded sebaceous gland carcinoma of the lower eyelid in a young pregnant patient

  • case report

Microplastics: Omnipresent and an ongoing challenge for medical science

  • Open Access
  • short report

Predictors of static and dynamic balance control in kidney transplant recipients

  • original article

MUW researcher of the month

  • MUW researcher of the month

Humoral and cellular response to the third COVID-19 vaccination in patients with inborn errors of immunity or mannose-binding lectin deficiency: correspondence

  • letter to the editors

Treatment of fecal incontinence—is there a light in the end of the tunnel?

  • Open Access
  • short report